Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: A multicenter study

Clinical Therapeutics

Volumn 20, Issue 2, 1998, Pages 283-291

  Koo, John ^a   Cuffie, Cynthia A ^b   Tanner, Daniel J ^b   Bressinck, Renie ^c   Cornell, Roger C ^d   DeVillez, Richard L ^e   Edwards, Libby ^f   Breneman, Debra L ^g   Piacquadio, Daniel J ^h   Guzzo, Cynthia A ⁱ   Monroe, Eugene W ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Research Solutions LLC   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f CAROLINAS MEDICAL CENTER   (United States)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j Milwaukee Medical Center SC   (United States)

more..

Author keywords

Combination therapy; Mometasone furoate; Psoriasis therapy; Salicylic acid

Indexed keywords

CORTICOSTEROID; KERATOLYTIC AGENT; MOMETASONE FUROATE; MOMETASONE FUROATE PLUS SALICYLIC ACID; SCH 471; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG MIXTURE; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; HYPERKERATOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OINTMENT; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SKIN ATROPHY; SKIN INFLAMMATION; SKIN IRRITATION; TOPICAL DRUG ADMINISTRATION;

EID: 7144254456     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80091-X     Document Type: Article

References (11)

1. Greaves MW, Weinstein GD. Treatment of psoriasis. NEJM. 1995;332:581-588.
2. Phillips TJ. Current treatment options in psoriasis. Hosp Pract. 1996;15:155-166.
3. Trozak DJ. Topical corticosteroid therapy in psoriasis vulgaris. Cutis. 1990;47: 341-350.
4. Medansky RS, Bressinck R, Cole GW, et al. Mometasone furoate ointment and cram 0.1 percent in treatment of psoriasis: Comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent. Cutis. 1988;42:480-485.
5. Rosenthal D, Duke E. A clinical investigation of the efficacy and safety of mometasone furoate ointment 0.1 % vs betamethasone valerate ointment 0.1 % in the treatment of psoriasis. Curr Ther Res. 1988;44:790-801.
6. Katz HI, Prawer SE, Watson MJ, et al. Mometasone furoate ointment 0.1 % vs hydrocortisone ointment 1.0% in psoriasis. Int J Dermatol. 1989;28:342-344.
7. Svensson A, Reidhav I, Gisslen P, et al. A comparative study of mometasone furoate ointment and betamethasone valerate ointment in patients with psoriasis vulgaris. Curr Ther Res. 1992;52:390-396.
8. Medansky RS, Brody NI, Kanof NB, et al. Clinical investigations of mometasone furoate - a novel, nonfluorinated, topical corticosteroid. Semin Dermatol. 1987;6: 94-100.
9. Weirich EG. Dermatopharmacology of salicylic acid. I. Range of dermatotherapeutic effects of salicylic acid. Dermatologica. 1975;151:268-273.
10. Krochmal L, Wang JCT, Patel B, Rodgers J. Topical corticosteroid compounding: Effects on physicochemical stability and skin penetration rate. J Am Acad Dermatol. 1989;21:979-984.
11. Elie R, Durocher LP, Kavalec EC. Effect of salicylic acid on the activity of betamethasone-17,21-dipropionate in the treatment of erythematous squamous dermatoses. J Int Med Res. 1983;11:108-112.